Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence

AIDS

Volumn 17, Issue 13, 2003, Pages 1990-1993

  Harwell, Joseph I ^a   Flanigan, Timothy P ^a   Mitty, Jennifer A ^a   Macalino, Grace E ^a   Caliendo, Angela M ^b   Ingersoll, Jessica ^b   Stenzel, Molly S ^c   Carpenter, Charles C J ^a   Cu Uvin, Susan ^a  

^a BROWN UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c Vancouver Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE TRANSMISSION; FEMALE; FEMALE GENITAL SYSTEM; GENE AMPLIFICATION; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LAVAGE; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX; VAGINA; VIRUS INFECTION; VIRUS LOAD;

ANTI-HIV AGENTS; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW-UP STUDIES; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PATIENT COMPLIANCE; RNA, VIRAL;

EID: 0041326846     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200309050-00021     Document Type: Article

References (27)

1. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai project study group. N Engl J Med 2000, 342:921-929.
2. Cu-Uvin S, Caliendo A. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women. Obstet Gynecol 1997, 90:739-743.
3. Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000, 14:415-421.
4. Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohen J, Landay A, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001, 358:1593-1601.
5. Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999, 15:1631-1638.
6. Kaufmann GR, Duncombe C, Cunningham P, Beveridge A, Carr A, Sayer D, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1 infected individuals. AIDS 1998, 12:1625-1630.
7. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.
8. Dickinson BP, Mitty JA, Mylonakis E, Rich JD, Merriman NA, Tashima KY, et al. Predictors of undetectable HIV plasma viral load in 250 HIV-positive women receiving care. AIDS 1998, 12:2075-2076.
9. Lucas GM, Cheerer LW, Chaisson RRE, Moore RD. Detrimental effect of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001, 27:251-259.
10. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002, 16:767-774.
11. Stein MD, Rich JD, Maksad J, Chen MH, Hu P, Sobota M, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000, 26:195-205.
12. Arnsten JH, Demas PA, Grant RW, Gourevich MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002, 17:377-381.
13. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Socio-demographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999, 13:1763-1769.
14. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996, 8:261-269.
15. Patterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
16. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001, 28:445-449.
17. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002, 34:984-990.
18. Farmer P, Leandre F, Mukherjee J, Gupta R, Tarter L, Kim JY. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull WHO 2001, 79:1145-1151.
19. Clarke S, Keenan E, Ryan M, Barry N, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Reader 2002, 12:305-316.
20. Lucas GM, Weidle PJ, Hader S, Moore R. Directly administered antiretroviral therapy (DAART) in a methadone maintenance clinic. Presented at An International Conference on Adherence to Antiviral Therapy. Dallas, Texas, 5-8 December 2002 [Abstract 35].
21. Conway B, Prusad J, Reynolds R, Farley J, Smith N, Meade A, Devlaming S. Nevirapine and protease inhibitor based regimens in a directly observed therapy program for intravenous drug users. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, 24-28 February 2002 [Abstract 545-T].
22. Cu-Uvin S, Caliendo AM. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women. Obstet Gy Gynecol 1997, 90:739-743.
23. Tyndall MW, Patrick D, Spittal P, Li K, O'Shaughnessy MV, Schechter MT. Risky sexual behaviors among injection drugs users with high HIV prevalence: implications for STD control. Sex Transm Infect 2002; 78 (Suppl. 1):i170-i175.
24. Kral AH, Blumenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001, 357:1397-1401.
25. Solomon L, Astemborski J, Warren D, Munoz A, Cohn S, Vlahov D, Nelson KE. Differences in risk factors for human immunodeficiency virus type 1 seroconversion among male and female intravenous drug users. Am J Epidemiol 1993, 137:892-898.
26. Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection amongong young adult short-term injection drug users. AIDS 2000, 14:717-726.
27. Watters JK, Estillo MJ, Kral AH, Lorvick JJ. HIV infection among female injection-drug users recruited in community settings. Sex Transm Dis 1994, 21:321-328.